Novocure Stock Price, News & Analysis

Novocure reported its Q1 2021 financial results, showing net revenues of $134.7 million, a 32% increase from Q1 2020. Gross profit rose 40% to $108.3 million, with a gross margin of 80%. However, the company experienced a net loss of $4.1 million, compared to a net income of $4.0 million in the previous year. Active patients rose 12% to 3,454, and prescription volumes remained stable. Novocure's ongoing clinical trials include pivotal studies for lung cancer and advanced liver cancer.

Novocure (NASDAQ: NVCR) has received FDA approval for its investigational device exemption (IDE) application to start the KEYNOTE-B36 trial, evaluating Tumor Treating Fields (TTFields) in combination with pembrolizumab for first-line treatment of advanced PD-L1 positive non-small cell lung cancer (NSCLC). The trial aims to enroll around 66 patients, focusing on objective response rate as the primary endpoint. Esteemed experts will guide enrollment and study execution. TTFields, an innovative therapy disrupting cancer cell division, is currently investigational for lung cancer.

Novocure (NASDAQ: NVCR) announced an update on the phase 3 LUNAR trial evaluating Tumor Treating Fields (TTFields) for stage 4 non-small cell lung cancer (NSCLC) after platinum failure. An independent data monitoring committee (DMC) recommended accelerating the interim analysis due to sufficient data from 210 patients. The DMC found no increased systemic toxicity and advised reducing the sample size to about 276 patients, which could expedite trial completion by over a year. Novocure plans to submit a protocol amendment to the FDA to incorporate these adjustments.

Novocure (NASDAQ: NVCR) announced 26 presentations at the AACR Annual Meeting 2021, highlighting the versatility of Tumor Treating Fields (TTFields) across various solid tumor types, including glioblastoma. Key findings include enhanced anti-tumor immunity and potential for combination therapies. Dr. Uri Weinberg emphasized the importance of ongoing research in understanding TTFields' role in cancer treatment. The research demonstrated that TTFields could disrupt cancer cell division, supporting its use alongside existing therapies.

Novocure (NASDAQ: NVCR) will announce its first quarter 2021 financial results on April 29, 2021, before U.S. markets open. A conference call will follow at 8 a.m. EDT, where management will discuss the results. Analysts can join via specific dialing codes, and the event will be accessible via Novocure's investor relations webpage, with recordings available for 14 days. Novocure is focused on innovative cancer therapies, especially its Tumor Treating Fields technology for aggressive cancers.

Novocure (NASDAQ: NVCR) reported strong financial results for Q4 and the full year 2020, achieving $144 million in Q4 net revenues, a 45% increase from 2019. Total annual revenue reached $494.4 million, marking a 41% growth. The company reported a net income of $4.9 million for Q4 and $19.8 million for the full year. Active patients grew by 17% to 3,411, with significant revenue gains in the U.S. (48%) and Greater China (132%). R&D expenses surged 85% to support clinical trials. Novocure's cash reserves increased to $842.6 million, bolstering future investments in its Tumor Treating Fields technology.

Novocure (NASDAQ: NVCR) has appointed Timothy J. Scannell to its board of directors as of February 5. Scannell, currently the President and COO of Stryker Corporation, brings extensive experience in medical technology. His expertise is expected to enhance Novocure's product development and drive innovation. Scannell will also serve on the Nominating and Corporate Governance Committee. Novocure focuses on advancing Tumor Treating Fields, a therapy for aggressive cancers, and has ongoing trials for various cancer types.

Novocure (NASDAQ: NVCR) announced preliminary unaudited net revenues and cash balances for Q4 and FY 2020, to be discussed at the 39th Annual J.P. Morgan Virtual Healthcare Conference. Key highlights include financial metrics, clinical developments, and future product plans. The company emphasizes its ongoing commitment to innovation in treatment options, particularly in oncology. Attendance at the conference aims to deepen investor engagement and showcase its strategic direction.

Novocure (NASDAQ: NVCR) will participate virtually in the 39^th Annual J.P. Morgan Healthcare Conference from January 11 to 14, 2021. William Doyle, Executive Chairman, will present on January 12 at 8:20 a.m. EST. The company will also engage in one-on-one meetings with investors. A live audio webcast of the presentation and materials will be available for replay for 14 days post-event.